Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Long-term survival with first-line nivolumab in advanced gastric cancer: Insights from CheckMate-649 and Korean experience (KINGCA Week 2026) - Oct 11, 2026 - Pres time: Sep 17, 2026; 01:00 PM - 01:20 PM; Location: Room D; "Sponsored by ONO Pharma korea, Bristol Myers Squibb." 
Clinical • Metastases • Gastric Cancer • Oncology • Solid Tumor
https://cdn.medsoft.co.kr/208/data/2026/KINGCA_WEEK_2026_Program_Book_FINAL.pdf
 
Jeesun Yoon
 
Oct 11, 2026
 
Prev Next